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ABSTRACT OF THE DISSERTATION
LOCALIZED SURFACE PLASMON RESONANCE BIOSENSORS FOR REAL-TIME
BIOMOLECULAR BINDING STUDY
by
Chang Liu
Florida International University, 2013
Miami, Florida
Professor Chenzhong Li, Major Professor
Surface Plasmon Resonance (SPR) and localized surface plasmon resonance
(LSPR) biosensors have brought a revolutionary change to in vitro study of biological
and biochemical processes due to its ability to measure extremely small changes in
surface refractive index (RI), binding equilibrium and kinetics. Strategies based on LSPR
have been employed to enhance the sensitivity for a variety of applications, such as
diagnosis of diseases, environmental analysis, food safety, and chemical threat detection.
In LSPR spectroscopy, absorption and scattering of light are greatly enhanced at
frequencies that excite the LSPR, resulting in a characteristic extinction spectrum that
depends on the RI of the surrounding medium.

Compositional and conformational

change within the surrounding medium near the sensing surface could therefore be
detected as shifts in the extinction spectrum.
This dissertation specifically focuses on the development and evaluation of highly
sensitive LSPR biosensors for in situ study of biomolecular binding process by
incorporating nanotechnology.

Compared to traditional methods for biomolecular

binding studies, LSPR-based biosensors offer real-time, label free detection. First, we
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modified the gold sensing surface of LSPR-based biosensors using nanomaterials such as
gold nanoparticles (AuNPs) and polymer to enhance surface absorption and sensitivity.
The performance of this type of biosensors was evaluated on the application of small
heavy metal molecule binding affinity study. This biosensor exhibited ~7 fold sensitivity
enhancement and binding kinetics measurement capability comparing to traditional
biosensors. Second, a miniaturized cell culture system was integrated into the LSPRbased biosensor system for the purpose of real-time biomarker signaling pathway studies
and drug efficacy studies with living cells. To the best of our knowledge, this is the first
LSPR-based sensing platform with the capability of living cell studies. We demonstrated
the living cell measurement ability by studying the VEGF signaling pathway in living
SKOV-3 cells. Results have shown that the VEGF secretion level from SKOV-3 cells is
0.0137 ± 0.0012 pg per cell.

Moreover, we have demonstrated bevacizumab drug

regulation to the VEGF signaling pathway using this biosensor. This sensing platform
could potentially help studying biomolecular binding kinetics which elucidates the
underlying mechanisms of biotransportation and drug delivery.
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Chapter 1

Introduction
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1.1. Motivation
The motivation of this dissertation was to develop localized surface plasmon resonance
(LSPR) sensors with enhanced sensitivity and capability of real-time kinetics
measurements.

Highly sensitive LSPR allows monitoring conformational change of

proteins, binding affinity as well as binding kinetics bwtween two organic or inorganic
molecules. This fundamental research could potentially benefit early diagnosis and drug
development. SPR was used as the platform technology as it provides several key
advantages such as high sensitivity, fast response time and label-free detection for
biomolecular binding measurements. The goal of the dissertation was to develop realtime, direct and simple LSPR sensors to measure all types of biomolecular binding,
which can be broadly classified as organic-inorganic bindings and organic-organic
bindings in this study.

1.2. Specific Aims and Hypothesis
Specific Aim 1: Development of highly sensitive LSPR sensor and its application on the
detection of small heavy metal molecule binding.

Protein conformational change induced by heavy metal molecule binding is small and
undetectable using traditional surface plasmon resonance (SPR). Thus the first aim of the
dissertation research was to fabricate a 3D hydrogel-nanoparticle based LSPR sensing
platform for sensitivity enhancement on this binding study. ArsA ATPase and ArsD
metallochaperone are two major sub-units of the arsenic detoxification pathway in charge
of cytosolic arsenic extrusion and transportation, respectively. ArsA-As(III) and ArsD-
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As(III) binding was used as models for sensor evaluations.

We expected to achieve enhanced sensitivity on the detection of ArsA - As(III) and
ArsD-As(III) binding with the 3D LSPR sensor comparing to the 2D LSPR sensor. The
association rate constant for ArsA-As(III) and ArsD-As(III) binding under different
conditions was investigated to help understanding the arsenic extrusion pathway.

Specific Aim 2: Sensing platform upgrade for biomarker study from living cell model.

Biomarkers comprise of cellular molecules such as proteins or nucleic acids that can be
detected in cells, blood, urine, or other body fluids and are over-expressed due to the
onset of disease. In order to measure cellular biomarkers using SPR, cells are usually
lysed to extract cytosolic biomarkers. The second aim deals with the development of a
direct, in situ sensing strategy to detect biomarkers released from living cells. Vascular
Endothelial Growth Factor (VEGF) related to many cancers was chosen as the model
analyte. It is a significant angiogenic factor that plays a crucial role in tumor growth and
metastasis. This sensing platform possesses unique potential on tumor early diagnosis
application, and most importantly on antineoplastic drug development.

We expected to detect VEGF from cancer cells in real-time. Some type of cancer cells
have relatively low VEGF secretion rate, stimulation can be used to induce rapid
exocytosis in order to measure the cell VEGF secretion level. The sensor can be used for
various applications such as drug development research, cellular and tissue level cancer
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studies, etc. The successful conception of this sensor will be an important step forward in
investigating VEGF and other biomarker release kinetics and drug regulation studies.

Specific Aim 3: Study of drug regulation on VEGF binding kinetics with living cell
model.

Monitoring biomarker release from living cells enables the study of drug regulation on
biomarkers and their receptors. Drug effects can be monitored on an in vitro living cells
model which mimics the in vivo biomarker signaling pathway. In order to evaluate the
LSPR sensor on drug regulation studys, a VEGF specific antineoplastic drug known as
bevacizumab was used as model analytes.

We employed the sensing platform achieved in specific aim 2 to monitor the drug
regulation of bevacizumab on the VEGF – VEGFR interaction. We expected to observe
high association rate between bevacizumab and VEGF. Due to the neutralization effect
of bevacizumab to VEGF, a lower association rate should be observed for VEGF –
VEGFR interaction when bevacizumab presents.

1.3. Biosensors
1.3.1. Historical Survey
Biosensors1 have received a lot of attention during the last 20 years because they find a
very broad range of applications such as diagnosis and monitoring of diseases,
environmental analysis, food analysis, as well as detection of illicit drugs, genotoxicity,
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chemical warfare agents, and drug screening.2

The development of biosensors

incorporates well established chemical sensing techniques with a bio-recognition
element. Recognition element’s current impact on biosensor technology rely on entities
such as antibodies, enzymes, nucleic acids, molecular imprints, or even cells and
tissues.3-5 Most biological systems have immune recognition systems through specific
binding interactions. Clark et al. and others first introduced biosensors in the 1950’s
combining physically entrapped enzymes to an electrochemical transducer.6-7 In recent
years, research efferts on biosensors has grown exponentially with researchers from
different backgrounds: engineers, chemists, physicists and clinical researchers. By the
year of 2015, the global market for biosensors is expected to grow to $12 billion with
point-of-care testing devices being the largest segment. Continuous growth in population
and aging population, and the consequent increase of chronic disease is the main driving
force of this market, which is expected to have continuous impact for decades. On the
other hand, growing needs of biosensors for research activities within medicine industry
are also innegligible. Applications such as drug discovery, drug analysis, in vivo and in
vitro test of pharmacodynamic effects require numerous studies with biosensors.

1.3.2. Definition and classification of biosensor
Biosensors are broadly defined as analytical devices that convert a biological response,
based on the composition, structure or function of a biological system, into an electrical
signal. Biosensors are often used to determine the concentration of analytes or to monitor
a biological system.6
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A successful biosensor should possess the following beneficial features:
1. Sensitivity: The response of the biosensor should be accurate and precise. The
signal to noise ratio of the biosensor should be high.
2. Specificity: The bio-recognition element of the biosensor must be highly specific
to the analysis.
3. Stability: The biosensor must be stable within a reasonable period under normal
storage conditions.
4. Reproducibility: The response of the biosensor should be reproducible and linear
over a relevant analytical range, without dilution or concentration.
5. Biocompatibility: If the biosensor is to be used for in-vivo monitoring in clinical
situations, the probe must be tiny and biocompatible, having no toxic or antigenic
effects. If the sensor is reusable then it should be able to withstand standard
sterilization procedures.
6. Economical & labor efficiency: The complete biosensor should be cheap, small,
portable and capable of being used by semi-skilled operators.
7. Market needs: There should be a market for the biosensor. There is no benefit to
developing a biosensor if other factors encourage the use of traditional methods.

Biosensor generally consists of 3 parts: the sensitive biological recognition element, the
signal transducer or the detector element, the biosensor reader device (Figure 1.1.).
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Figure 1.1. A schematic illustration of the main components of biosensors.

1. The sensitive biological recognition element, which can be, but are not limited to
tissue, cells, microorganisms, cellular receptors, enzymes, antibodies, nucleic
acids, aptamers, etc. Generally, it should be a biologically derived material or
biomimic component that binds or recognises the analyte under study.
2. The signal transducer or the detector element (optical, electrochemical, thermal,
piezoelectric, mass etc.) that transforms the signal generated by the interaction
between the analyte and the biological recognition element into a signal that can
be quantitivly measured.
3. The biosensor reader device consists of associated electronics (signal processors,
amplifiers, digital detectors, etc.) that are responsible for the display of the data in
a user-friendly manner.
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1.4. Surface Plasmon Resonance Biosensors
The principle of SPR biosensors is the measurement of refractive index changes at a
plane interface between two media with dielectric constants of opposite signs, a dielectric
and a metal such as gold (because it gives an SPR signal at convenient combinations of
reflectance angle and wavelength and is chemically inert), when a wedge of polarized
light, under conditions of total internal reflection, is directed towards the glass face of the
sensor surface (Figure 1.2.a).8 An electric field, known as evanescent wave, is generated
when the polarized light strikes the glass. This evanescent wave interacts with, and is
absorbed by, free electron clouds in the metal layer, generating electron charge density
waves called plasmon that propagate parallel along the metal/dielectric interface, as can
be appreciated in Figure 1.2.b by Badia et al., causing a reduction in the intensity of the
reflected light. No photons exit the reflecting surface, but their electric field decreases
exponentially with distance from the interface, decaying over a distance of ~1/4
wavelength beyond the surface. The resonant angle at which a minimal in intensity of
reflected light occurs is a function of the local refractive index at or near the gold
surface.9-11 Thus, the most important point in relation to the experiments is that a change
in the bulk refractive index of the dielectricum medium and the adsorption or desorption
of molecules from the metal surface changes the refractive index at the metal-dielectric
interface and results in changes in the SPR signal. LSPR is excited by a similar method
to SPR excitation. However, SPR is generated on a planar metal surface, whereas LSPR
is generated on a nano-structure surface. Such nano-structure causes a shorter decay
length of light when penetrating the surface, therefore offers a higher spatial resolution
and higher sensitivity than SPR.
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Figure 1.2. (a) Kretschmann configuration SPR, (b) Plasmon propagation parallel along the
metal/dielectric interface

SPR is generated by linearly polarized light, with its electric (E) field vector elther
parallel or perpendicular (Figure 1.3) to the plane of incidence. Such polarized light is
named p- or s- polarized light. For the p-polarized light illustrated in Figure 1.3, there is
an E-field component perpendicular to the interface Ez=|E|cos(θ). As the definition of
dielectric permittivity, ε1=(n1)2 and ε2=(n2)2 (medium 1=glass, medium 2=metal). We
assume that the media does not absorb light: ε0 ε1 Ez1=ε0 ε2 Ez2.
Since ε1≠ε2 (n1≠n1)  Ez1≠Ez2, the change in Ez means the polarization charge
distribution across the interface is discontinuous. This change in Ez will give rise to the
creation of electron charge density waves at the boundary. On the other hand, s-polarized
light has no Ez component, it cannot be utilized for generation of SPR.
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Figure 1.3. Illustration of p-polarized light made incident on a planar interface of two medium.
For a typical SPR instrument, medium 1 is a dielectric material such as glass, medium 2 is a metal
such as gold.

Earlier applications of LSPR biosensors were mainly focused on the interaction
characterization of single molecules between each other: protein/protein, nucleic
acid/protein, or nucleic acid/nucleic acid interactions.12-13 In 2008, Miura’s group
demonstrated a prototype field portable LSPR system using monoclonal trinitrotoluene
(TNT) antibody modified AuNPs for detection of TNT.14 They achieved a detectable
range of 10 ppt to 100 ppb, which is four-fold more sensitive than that in the absence of
AuNPs. Using a similar principle, Kim’s group recently constructed an LSPR biosensor
based on subwavelength 1D and 2D gold nanoarrays built on a thin gold film for the
detection of avian influenza DNA hybridization.15

Their results showed that 1D

nanogratings exhibited four-fold amplification of the SPR signal, and 2D nanohole arrays
exhibited a 2.5-fold increase in amplification.

Although such technologies have

successfully demonstrated high detection sensitivity in the range of picomolar of
analytes, small molecules such as heavy metal ions have had difficulty being measured
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using this current setup. On the other hand, studies have addressed cellular structures,16
such as artificial membranes17 and even whole biological organisms18 as interaction
partners play a pivotal role.

Especially for the development of medical and

pharmaceutical assay formats, utilizing LSPR biosensors, the shift from single-molecules
interactions to the whole cell system with its complex regulation pathways is necessary.
Many cellular activities can be evaluated by the change of cell secretions. SPR has also
been utilized on cellular level studies through detecting proteins or biomarkers in cell
secretions. In 2007, Li et al. demonstrated the detection of VEGF using SPR with
detection sensitivity down to subpicomolar. RNA aptamer microarrays were used to
capture the VEGF on the sensing surface. Another antibody-horseradish peroxidase layer
was linked on top of the VEGF as a sandwitch layer. 5, 5′-tetramethylbenzidine was also
immobilized on the sensing surface.

The localized horseradish peroxidase - 5,5′-

tetramethylbenzidine precipitation reaction was used to amplify the SPR response.19 Yu
et al. studied the interaction between Bevacizumab (an antibody based drug for VEGF
regulation) and VEGF using SPR in 2008. Bevacizumab was found to specifically bind
to human VEGF. It is not a suitable drug for studies involving murine VEGF.20 Similar
to these two studies, many published studies on the detection of proteins and biomarkers
exocytosis using SPR only demonstrated the detection of analytes from solution.
Moreover, Kyo et al. developed a SPR sensing platform to detect proteins from crude
cells lysate. This study has shown the specificity of SPR with a real biological fluid.21
Another research group developed a SPR based sensing strategy to monitor the
intracellular superoxide dismutase in E coli..22

Both of these stuies have achieved

sensitive, label-free detection of analytes from cells. However, cells were lysed to collect
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analytes for SPR measurements. The lysing process may potentially induce variations to
cellular secretions and cause false results. Till date, there is a lack of a non-invasive SPR
sensing platform for cellular secretion studies.

Figure 1.4 shows the BI-2000 flow injection SPR instrument that we employed in this
dissertation study. The instrument consists of two modules: a control module and a
precision syringe pump. The control module generates a 670nm laser for the excitation
of SPR. This laser makes incident on the SPR sensing surface after going through a
prism. A flow cell is attached on top of the sensing surface. The precision syringe pump
and the sample injection port are connected to the flow cell to provide a continuous flow
of environmental buffer and to introduce samples to the sensing surface, respectively.

Figure 1.4. A picture of the BI-2000 flow injection SPR instrument.

A typical SPR sensorgram usually consists of the following curves (Figure 1.5):
1. Baseline: A stable baseline is the reference for SPR angle shift induced by surface
binding. It is usually obtained by washing the surface with flowing buffer for 35min.
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2. Association curve: After the injection of the analyte, SPR basline will increase
and reach a maximum point. This process indicates the analyte passing through
the surface and binding to the surface ligand. Binding affinity information can be
obtained from this curve.
3. Dissociation curve: This process occur at the end of the injection, unbound
analyte is carried away by the flowing buffer. The baseline shift value (mDeg)
after the dissociation curve bears information of the concentration of analyte.
4. Regeneration (optional): The sensing surface can be regenerated by reagent such
as HCl or NaOH for reuse.

Figure 1.5. The sensorgram of baseline, association, dissociation and regeneration processes
during a typical SPR experiment. (laboratory for genomics and bioinformatics, University of
Oklahoma health sciences center)

Furthermore, recent developments of LSPR sensors focusing on a reduction in device
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size,23 imaging applications,24 and multichannel sensing12 have increased their
significance. This great interest and development of LSPR sensors is due to its high
sensitivity, selectivity, speed, and reliability in analysis.

1.5. Other Methods for Binding Measurements
1.5.1. Current Methods to Measure Protein-Arsenic binding
Current methods used for As (III)-Ars proteins binding study are extended x-ray
absorption fine structure (EXAFS), fluorescence excitation spectra, gel filtration, etc.25
However, all aforementioned methods are associated with several disadvantages and
limitations. EXAFS is a definitive method for analyzing metal ligands but lacks
sensitivity and real-time analysis. It thus requires intensive labor to reveal binding
kinetic information from uncontinuous data. Furthermore, EXAFS technique necessitates
highly sophisticated, expensive detection equipment. Fluorescence excitation spectra
provide real time data acquisition in the millisecond range but cannot offer direct binding
information.

Binding process is studied by measuring changes in fluorescence

anisotropy. Gel filtration technique for protein separation lacks accuracy due to residue
on columns. In addition, most of these equipments require trained personnel to use and
maintain which add to the diagnosis costs. Therefore, these techniques are not suitable to
be used to study real-time binding affinity and kinetics.

1.5.2. Current Methods to Measure Biomarkers
Enzyme-linked immunosorbent assay (ELISA), fluorescence correlation spectroscopy,
electrochemistry and Western Blotting, etc. are commonly used methods for detection of
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biomarkers.26-27 However, all aforementioned methods are associated with several
disadvantages and limitations. For instance, ELISA technique lacks sensitivity,
reproducibility and real-time dynamic detection capabilities. Immunoassay techniques
also require intensive labor work from trained personnel. Fluorescence spectroscopy
techniques may be used for highly sensitive biomarker detection, but they require
labeling samples with fluorescence dye. Electrochemistry sensing techniques offer time
and cost effective, highly sensitive strategy for biomarker detection. However, the major
limitation of electrochemistry sensing is that it requires sample to be electrochemically
active. SPR sensing platform in this proposed work is widely used in the past two
decades in the application of diagnosis and monitoring diseases, environmental analysis,
food analysis, as well as drug screening. SPR constitutes a very interesting alternative
due to their advantages in the study of biomarker:28
•

High sensitivity (subnanogram mass or subnanometer thickness of the surface
bound layer)

•

No need to label the analyte molecules, minimizing the potential negative impact
of the label on their biological or chemical function.

•

Real-time monitoring of recognition processes in situ; this constitutes an
important driving force in biosensor research focused in the development of largescale biosensor arrays composed of highly miniaturized signal transducer
elements that enable the real-time and parallel monitoring of multiple species.

•

Ability to detect interactions at solid/liquid interfaces, which are involved in many
biologically relevant recognition processes.

However, there are also several disadvantages associated to the SPR biosensor. The main
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disadvantages are their high cost and lack of portability. A typical commercialized SPR
instrument can cost $50,000 to 500,000 with a size larger than a desktop computer. SPR
is also lack of simultaneous measurement capability, which makes it not suitable for high
throughput applications.

1.6. Polymer Brushes for Biosensing Signal Enhancement
Polymer brushes may form ultrathin coatings, usually from block copolymers or endgrafted polymers that are tethered with one chain end to an interface, which is generally a
solid substrate.29

Polymer brushes exhibit a behavior that is comparable with self-

assembled monolayer (SAM). If appropriate monomers are used, they provide a pathway
for the fabrication of versatile adaptive surfaces capable of responding to changes of
temperature, solvent polarity, pH, and other stimuli, generally by reversible swelling.30
Polymer brushes are mainly applied onto surfaces by: (a) Physisorption; (b) LangmuirBlodgett technique; (c) The “grafting to” approach, also called, chemisorption, which
involves the formation of covalent bonds between a polymer previously prepared and the
surface; and (d) The “grafting from” approach, which involves the polymerization of the
monomer or monomers from functionalized surfaces (also called surface initiated
polymerization, SIP, or surface mediated polymerizations, SMP). This work employed
surface initiated radical polymerization for the following significant advantage:
•

Better control of brush thickness, composition, and architecture

•

Broad choice of monomer

•

Compatibility with both aqueous and organic media

•

High tolerance toward a wide range of functional groups
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Poly(N-isopropylacrylamide) (PNIPAAm) is one of the most widely studied polymer.31-32
This non-ionic polymer undergoes a sharp hydrophilic-hydrophobic transition in aqueous
solution at 32ºC.

Such property that has a variety of applications in many fields,

including solute extraction and separation, controlled drug release,33 artificial organs,34
and enzyme immobilization, with the swellable hydrogels prepared by polymer
crosslinking. PNIPAAm brushes have previously been grafted form different substrates
and employed for the fabrication of functional surfaces capable of a reversible transition
between hydrophilic and hydrophobic character when subjected to changes in
temperature, and also have been combined with nanopatterning strategies.

Other

polymers such as poly(acrylic acid) (PAAc) and poly(vinyl pyridine) (PVP) respond to
changes in pH.35 PAAc, which is hydrophobic in its protonated state (pH < 4) becomes
hydrophilic after deprotonation.36 PVP is also a pH dependent polymer that behaves as a
hydrogel;37 it is hydrophobic in its deprotonated state (pH > 5) and becomes water
soluble in its protonated state (pH < 5). In spite of the characteristics of the intelligent
polymers previously mentioned, the preparation of their copolymers results more
interesting for sensing applications, since the combination of polymers with different
characteristics allow the modulation of the final properties of the materials in the process
that couples molecular recognition with swelling and shrinking processes.

1.7. Arsenic Detoxification Research
Arsenic is one of the most prevalent environmental toxins. The natural content of arsenic
found in soils varies between 0.01 mg/kg and a few hundred milligrams per kilogram.
Arsenic is a component of over 245 minerals. Volcano activities and other geological
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process are sources of the high arsenic concentrations in the environment.38 Human
activities are also significant sources of arsenic contamination in water and soil:
•

The disposal of industrial waste chemicals

•

The smelting of arsenic bearing minerals

•

The burning of fossil fuels

•

The application of arsenic compounds in many products especially in the past few
hundred years

Arsenic exists in nature in the oxidation states +V (arsenate), +III (arsenite), 0 (arsenic)
and -III (arsine). In the aqueous environment, inorganic arsenic commonly exists in
oxidation states as arsenous acid (As(III)), arsenic acid (As(V)), and their salts. Organic
arsenic compounds such as monomethylarsonic acid (MMA), dimethylarsinic acid
(DMA) are usually less toxic than inorganic arsenic compounds. Acute and chronic
arsenic poisoning may cause disorder of cardio-vascular, nervous, respiratory and gastrointestinal system. Moreover, Arsenic is a carcinogenic and may cause lung cancer,
bladder cancer, liver cancer and etc.

Today, arsenic contamination in drinking water is commonly found in India (WestBengal), Vietnam, Taiwan, Mexico, Argentina, Chile, Hungary, Romania, and many
parts of the United States.39-40 WHO research reveals that over 40 million people are
acute at risk of arsenic groundwater problems in Bangladesh. Consequently, the chronic
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toxicity of arsenic will be a common cause of death in Bangladesh.

1.8. Current Chemotherapeutic Therapy and VEGF Regulation Therapy
Chemotherapy is the treatment of cancer with an antineoplastic drug or with a
combination of such drugs. It is the most commonly used treatment for a vast majority of
human tumors. Principally, chemotherapeutic drugs kill cells with a rapid dividing rate.
However, they also harm cells that divide rapidly under normal circumstances, such as
cells in the bone marrow, digestive tract and hair follicles, thus results in the most
common side effects of chemotherapy: myelosuppression, mucositis and alopecia.41 In
the broad sense, most chemotherapeutic drugs work by impairing mitosis, effectively
targeting fast-dividing cells and cause cells to undergo apoptosis.

The majority of chemotherapeutic drugs can be divided into following categories:
antimetabolites, alkaloids and terpenoids inhibitors, cytotoxic antibiotics and other
antitumour agents. Doxorubicin is one of the most widely studied cytotoxic antibiotics.
It is commonly used to treat a wide range of cancer but with a serious adverse effect of
heart damage. Doxorubicin interacts with the cell DNA by intercalation and inhibition of
molecular biosynthesis, preventing the DNA double helix from being resealed and
thereby stopping the process of replication.42 Bevacizumab is a humanized monoclonal
antibody that inhibits VEGF-A. It is currently used as an angiogenesis inhibitor to stop
tumor growth by preventing the formation of new blood vessels. Thrombospondin (TSP)
is an antiangiogenic which inhibits the proliferation and migration of endothelial cells by
interactions with CD36 expressed on their surface of these cells.
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All aforementioned antineoplastic solutions are controversial due to adverse effects,
molecular weight, unclear mechanism and limited availability. Therefore, research for
development of newer anticancer drugs one of the most funded research by National
Institutes of Health (NIH). During the period from 2005 through 2010, the National
Cancer Institute (NCI) budget averaged $4.9 billion per year.

Human cells rely on a constant oxygen supply to maintain their cellular activity.
Therefore all of our cells are within a tenth of a millimeter from a blood capillary which
delivers oxygen via blood to cells. Tumor cells are no exception and even more hungry
on blood supply. A tumor larger than a millimeter will starve itself of oxygen and energy
unless new blood vessels are built to provide a supply. For this reason, many cancer cells
employ the normal processes of angiogenesis in order to build their own blood supply.43

VEGF is a signal protein produced by oxygen-hungry cells to promote growth of blood
vessels. It binds to specialized receptors on the surfaces of endothelial cells and directs
them to build new vessels. Tumor cells use the same process to build their own oxygen
supply.

They produce abnormally large amount of VEGF or block the action of

angiogenesis inhibitors. This action is termed as “angiogenic switch”, giving the ability
of metastasis to the tumor, since a custom-made blood supply can be constructed
wherever new tumors begin to grow.44-45

VEGF secretion level directly reveals the tumor size, growth stage and malignancy.
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Therefore, VEGF secretion rate measurement from living cancer cell culture is essential
to prediction and early diagnosis of cancers. Taking advantage of the highly sensitive
detection capabilities of SPR, we used it to measure VEGF secretion amount from a
certain number of cancer cells in real-time, thus to calculate the average single cell VEGF
secretion rate. The time resolution of VEGF release was monitored previously on a scale
of several hours or days due to the limitations of the detection techniques available. By
using SPR biosensors we were able to measure VEGF release on a scale of microseconds.
Due to the highly sensitive detection possible using SPR even the slightest release of
VEGF from the cancer cells can be instantaneously mapped.

VEGF secretion is also an attractive process for the development of newer cancer
therapy. Blood supply to the tumor can be cut off by selective inhibition of VEGF
production or binding to its receptor using drugs or antibodies.46 A large amount of drugs
and antibodies are currently being tested by different research groups to modulate VEGF
production in cancer cells. To develop suitable drugs for this propose, bind process of
VEGF-drug or VEGFR-drug interaction is a significant factor. The unique real-time
recoding feature of SPR enables us to monitor the association and dissociation curve of
the binding process, which provided the binding association constant value for each drug
sample.
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Chapter 2

Development of the highly sensitive LSPR sensor
and its application on the detection of small heavy metal molecule binding
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2.1. Introduction
Surface plasmon resonance has brought a revolutionary change to in vitro study of
biological and biochemical processes due to its ability to measure extremely small
changes in RI, binding equilibrium and kinetics.47-51 Strategies based on plasmonic
nanoparticles have been employed to enhance the sensitivity for a variety of applications,
such as diagnosis of diseases, environmental analysis, food safety, and chemical threat
detection.52 Theoretically, SPR can be induced only in free electron metals, e.g., Au, Ag
and Cu, due to the interaction of surface electrons with the electromagnetic wave and the
contribution from the interband transition of the d-shell electrons.53 At the end of the
1990s, several research groups had begun exploring schemes for the development of
LSPR biosensors using noble metal nanoparticles because of the extremely sensitive
nature of their electron-rich surfaces to the surrounding environment. Based on the Mie
theory, when an electromagnetic wave is directed to the metallic nanoparticle, an induced
oscillation of free electrons occurs at the surface, resulting in a characteristic extinction
spectrum that depends on the type of metal, the size and shape of the nanoparticles,
interparticle distance and most importantly, the RI of the surrounding medium.54-55
Compositional and conformational changes within the surrounding dielectric medium
near a nanoparticle could therefore be detected as shifts in the extinction spectrum.
LSPR spectroscopy operates in a manner that is analogous to SPR to induce the
extinction spectrum, however, the electromagnetic field of LSPR decays within a much
smaller length than in SPR, which gives significant rise to the sensitivity of LSPR
sensors.
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The fabrication of the metallic nanostructure on the LSPR sensing layer is traditionally
performed by “2D” methods. DebRoy’s group immobilized polyclonal antibodies for
Escherichia coli (E.coli) O157:H7 using biotin–neutravidin binding to detect E. coli
O157:H7 spiked in pasteurized milk (skim-milk), apple juice, and ground beef extract.56
They also functionalized a SPR gold chip with carboxymethylated dextran layer followed
by Protein A to immobilize polyclonal antibodies against E. coli or Salmonella
Enteritidis.57 In these cases, low concentration targets in the sample were difficult to
detect because of the limited interaction time with the sensing surface due to continuous
flow. Signal amplification is a common strategy for detection of low concentrations of
target molecules.

Cheng’s research group recently reported a novel SPR signal

amplification strategy based on in situ surface-initiated atom transfer radical
polymerization,58 in which a polymer was used as a label for small molecules. Another
feasible strategy is the functionalization of the SPR sensor chip with an absorbtive
coating in addition to using bare nanoscale noble metal structures for amplifying the
sensor response. Radical copolymers would be ideal materials for this purpose due to
their high capacity for absorbing the analyte via a swelling-shrinking process upon
interacting with a water based buffer, enabling the sensing surface to capture larger
amount of analyte.59

This property allows interparticle distance tuning.

Poly (N-

isopropylacrylamide) is a promising material that can satisfy these requirements.60
Furthermore, copolymers obtained from the combination of polymers may result in even
more sensing applications, as polymers with different functional groups allow the
modulation of the material’s final properties for recognizing different analytes. Finally,
radical copolymers prevent non-specific binding to the remaining free gold surface in
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between the probes.

This method is comparable to the conventional immunoassay

approach in which the surface is masked with a high concentration of a non-specific
protein such as bovine serum albumin or denatured casein.61

Arsenic (As) is one of the most common toxic elements in the environment and is
introduced by both geochemical and anthropogenic sources. Exposure to this metalloid
leads to cancer, cardiovascular and peripheral vascular diseases, diabetes and
neurological disease.62 The field of arsenic detoxification has been studied for many
decades. Nearly every organism, from bacteria to humans, has an arsenic detoxifying
system. In bacteria and archaea, the genes for arsenic resistance are usually found in
arsenical resistance (ars) operons. One such operon, the ars operon of plasmid R773,
produces resistance to trivalent and pentavalent salts of the metalloids arsenic and
antimony in cells of E. coli catalyzed by an Adenosine-5'-triphosphate (ATP)-coupled
As(OH)3 extrusion pump.63 The operon has five genes, arsRDABC.64 Among them,
ArsR is a transacting repressor protein that homeostatically regulates the levels of ars
transcription.65 ArsD is an As(III) chaperone that binds and transfers cytosolic arsenite
to ArsA, an As(III)-activated ATPase.66 Together ArsA and ArsB, a transmembrane
arsenite antiporter, form the ATP-driven ArsAB As(OH)3 extrusion pump.67 In 2006,
Tao’s group reported the first application of SPR sensing for arsenic detection in
groundwater.68 However, there are no reports that utilize this technique for kinetics study
on arsenic transportation and detoxification to date.

In this study, we integrated in situ radical copolymerization and AuNPs to construct a
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novel LSPR sensing system.

By growing 3D AuNPs-doped PNIPAAm-co-PAAc

hydrogel-based coating on the gold sensing surface, we observed a 6.8-fold enhancement
of LSPR signal comparing to the traditional 2D AuNPs-decorated gold sensing surface.
We applied this LSPR sensor to study the binding kinetics of the ArsA ATPase for
As(III) in the presence of adenosine-5’-triphosphate and magnesium ion (MgATP) and
ArsD. In previous studies, binding of As(III) by Ars proteins was performed by methods
such as EXAFS.25 EXAFS is a definitive method for analyzing metal ligands but lacks
sensitivity and real-time analysis. In contrast, our 3D hydrogel based LSPR sensing
strategy obtained direct, real-time binding kinetic information.69

Thus, in addition to

providing a means of amplifying the LSPR response, this work presents a novel approach
to study the kinetic behavior of the arsenic extrusion pathway. Finally, the functionality
of our novel 3D hydrogel-nanoparticle coating can be easily modified by changing or
adjusting loading of monomers, it has potential to be broadly applied to sensing a range
of biological analytes.

2.2. Experimental
2.2.1. Materials
Allylmercaptan,

acrylic

acid

(AAc),

N-isopropylacrylamide

(NIPAAm),

N,N-

methylenebisacrylamide (BIS) were purchased from Acros Organic (New Jersey),
2,2’azobisisobutyronitrile (AIBN) and diisopropylfluorophosphate (DIFP) were obtained
from Sigma-Aldrich (St. Louis, MO).

11- mercaptoundecanoicacid (MUA) was

purchased from Asemblon (Redmond, WA). Cystamine dihydrochloride was obtained
from Spectrum (New Brunswick, NJ). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
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hydrochloride (EDC), N-Hydroxysuccinamide (NHS) and hydrogen tetrachloroaurate
(HAuCl4) were obtained from Alfa Aesar (WardHill, MA).

Trisodium citrate

(Na3C6H5O7) and dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific
(Waltham, MA). All reagents and solvents were used as received.

2.2.2. Protein expression and purification
Cells bearing the indicated plasmids were grown in Lysogeny Broth (LB) medium over
night at 37°C and then diluted 50-fold into 1 L of the same medium. Proteins were
expressed by induction with 0.3 mM isopropyl-ß-D-thiogalactopyranoside at A600 of 0.6–
0.8 for 3 h. ArsA with a six histidine tag at the C-terminus was purified from cells of
strain BL21 (DE3) expressing pAlter-1-dAhB plasmid, as described.70

Cells were

harvested by centrifugation and washed once with a buffer containing 50 mM 3-(Nmorpholino)propanesulfonic acid (MOPS), pH 7.5, 0.5M NaCl, 30mM imidazole and
10mM 2-mercaptoethanol (Buffer A). The cells were suspended in 5 mL of Buffer A per
gram of wet cells and lysed by a single passage through a French press at 20,000 psi.
DIFP was added at 2.5 mL/g wet cells immediately following French press. Unbroken
cells and membranes were removed by centrifugation at 150,000xg for 1h at 4°C. The
supernatant was loaded to 10mL Probond Ni-column (Invitrogen) pre-equilibrated with
Buffer A. Unbound proteins were washed by 60 mL of buffer A, and ArsA was eluted
with imidazole gradient generated by Buffer A and Buffer B (50 mM MOPS, pH 7.5,
0.5M NaCl, 300mM imidazole and 10mM 2-mercaptoethanol), followed by addition of
0.25 mM Ethylenediaminetetraacetic acid (EDTA) and 5 mM Dithiothreitol (DTT) to
each fraction.

ArsA containing fractions were identified by sodium dodecyl sulfate
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polyacrylamide gel electrophoresis (SDS- PAGE), pooled, concentrated by Amicon
Ultra-15 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore), mixed with 10%
glycerol, aliquoted and stored at -80°C until use. ArsD and its derivatives with a six
histidine tag at the N-terminus were purified similarly. Purified proteins were stored at 80°C until use, and their concentrations were determined according to the method of
Bradford71 or from the absorption at 280nm.72

2.2.3. Preparation of gold nanoparticles
Colloidal gold nanoparticles used in this study were prepared by citrate reduction of
HAuCl4 in aqueous solution.73 The formation of gold nanoparticles can be observed by a
change of color. Briefly, HAuCl4 and sodium citrate solutions were filtered through a
22µm microporous membrane filter prior to use. HAuCl4 (40mL, 1.0mM) was then
added to an Erlenmeyer flask (250mL), vigorously stirred and brought to a boil on a hot
plate. Following this, 3.5mL of 1% trisodium citrate was added to the vortex of the
boiling solution. 100nm Au particles were formed 2min after the addition of trisodium
citrate and 15nm AuNPs were obtained if the solution was stirred for an additional 10
min. A layer of absorbed citrate anions on the surface of the nanoparticles prevents
aggregation. The particle size was determined by a ZEN3600 Zetasizer from Malvern
Instruments, Inc. (Westborough, MA).

2.2.4. In situ polymerization
A stock of amino group modified AuNPs was prepared by incubating bare AuNPs in
1mM cystamine dihydrochloride solution for 12h at 4°C. Following this, 400µmol Aac
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was added to the amino modified AuNPs and incubated under the presence of NHS/EDC
for 30min to form covalent linkage (pH = 7.4).

The resulting solution was then

centrifuged at 7000 RCF for 10min and the sediment was washed and resuspended with a
same volume of DMSO for further use (not shown in Scheme 2.1.). A gold SPR chip
was cleaned using piranha solution for 2 min and rinsed with copious ethanol. The
cleaned gold chip was incubated in a 10mM allylmercaptan/ethanol solution afterward
for 12 h at room temperature in the absence of light. Lastly, the chip was rinsed three
times with ethanol and DMSO shortly prior to use to remove all the unbounded
allylmercaptan residual. The in situ polymerization was carried out in the following
manner: 5mL DMSO containing 950µmol of NIPAAm, 150µmol of AuNPs linked AAc,
250µmol of AAc, 58µmol of cross linking agent BIS and 805µmol of AIBN as the
initiator were first added along with the gold chip into a three-neck round bottom flask
(Figure 2.1). The resulting solution was degassed by passage of a stream of nitrogen for
a minimum of 20min and then heated at 60°C for 110min in nitrogen environment
(Scheme 2.1). After polymerization, the AuNPs doped PNIPAAm-co-PAAc polymercoated gold chip was
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Scheme 2.1. (A) Cartoon representation of the swelling-shrinking process of the copolymer for
LSPR signal amplification and immobilization of ArsA ATPase. (B) Structural illustration of the
in situ radical copolymerization of PNIPAAm-co-PAAc hydrogel.
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washed with DMSO, ethanol and water in order to remove any non-bonded copolymer
and unreacted monomers. Finally, the chip was stored under vacuum to remove any
water absorbed in the hydrogel before LSPR experiment.

Control chips were also

prepared by deposition of bare AuNPs on SPR chips and functionalized with carboxylic
groups using MUA for characterization purposes.

Figure 2.1. Experimental setup of the in situ radical copolymerization

2.2.5. Experimental setup and conditions
2.2.5.1. Surface characterization
Fourier transform infrared spectroscopy by attenuated total reflectance (ATR-FTIR) was
carried out using a FTIR-4100 spectrometer (Easton, MD) with a maximum resolution of
0.9 cm.

A Nanoscope 3A atomic force microscope (AFM) obtained from Veeco
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(Plainview, NY) was employed to measure the thickness of the polymer thin film on the
gold chip. Briefly, a 10×10 µm2 area of the polymer layer was scratched and removed
using a contact mode AFM cantilever (spring constant 0.2Nm) under the load of 500nN
force. To determine the depth of the scratched area, the morphology of a 30×30 µm2 area
covering the scratched area was imaged by AFM under a 25N force load with a scanning
speed of 2Hz. A JSM6330F field emission scanning electron microscopy (SEM) from
JEOL (Peabody, MA) was employed for observing the surface morphology and
component of the LSPR sensing surface.

2.2.5.2. Preparation of LSPR measurement
A BI-2000 SPR instrument was purchased from Biosensing Instrument (Tempe, AZ). A
gold SPR chip (20mm×20mm×1mm), which is a BK7 glass slide coated with a 45nm
layer of gold over a 5nm layer of chromium, was mounted on the upper face of the BK7
prism with the gold layer facing upward. A 3-5 µL drop of index matching fluid (World
Precision Instruments, Inc., FL) was applied between the glass face of the chip and the
prism with care so that no air bubbles were trapped at the interface. Following this, a
biocompatible polydimethylsiloxane (PDMS) microfluidic injection chamber gasket with
a 5mm×1.7mm×125µm channel was clamped to the gold face of the chip. A dual syringe
pump was attached to the injection chamber allowing both sample and reference buffer
flow through the sensing surface. All buffers and solutions were degassed by vigorously
stirring and purging with nitrogen before introduction into the injection system to avoid
oxidation of ArsA ATPase and ArsD metallochaperone protein by air. Data collection
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and instrument control was performed using the Biosensing Instrument SPR Control
Program running on a PC.

In the LSPR experiment, a 670nm wave length laser with a 72.2° incident angle was
employed as the light source. The sensing surface was flushed by 50mM MOPS buffer
(pH 7.5) at a 150 µL/min flow rate until a stable SPR baseline was acquired. In general,
a 100-150mDeg SPR angle shift would be observed during this process due to the
swelling of the PNIPAAm-co-PAAc hydrogel upon introduction of water based MOPS
buffer. The MOPS flow rate was then reduced to 50µL/min for optimized binding time
and maintained during the whole LSPR measurement. All measurements were carried out
in MPOS buffer environment unless otherwise stated.

In order to demonstrate the enhanced sensitivity by the polymer hydrogel thin layer as the
immobilization and sensing material, as well as its suitability for binding kinetic study,
ArsA ATPase was coupled to the carboxylic groups of AAc and the specific interaction
of As(III) with the immobilized ArsA was observed by LSPR. Initially, carboxylic
groups of the polymer layer were activated with a solution of EDC (75mM) and NHS
(15mM) at an injection rate of 20µL/min (denoted as X in Scheme 2.1.). ArsA in MOPS
with a concentration of 50µg/mL was injected with a same rate and allowed to react with
the activated polymer for 4min to form a covalent linkage between the surface carboxylic
groups and the ArsA amino-groups.

This was followed by an addition of stepped

concentration of As(III) to study the binding kinetics and capacity of the ArsA ATPase.
Finally, the above experiment was repeated using control chips coated only with AuNPs.

33

2.3. Results and discussion
2.3.1. Surface morphology and composition characterization
To verify the incorporation of NIPAAm and AAc monomeric units in the copolymer
grown from the allylmercaptan-modified gold surface, ATR-FTIR spectra were taken
from the polymer coated gold chip surface. As a result, Figure 2.1. shows a region of the
ATR-FTIR spectrum obtained, which confirms the presence of both NIPAm and AAc in
the thin film. The main bands at located at 1651 and 1551cm correspond to the carbonyl
stretching of the amide group (amide I band) and to the N–H stretching of the secondary
amide (amide II band), respectively. On the other hand, the appearance of a much less
intense absorption band at 1716 cm, characteristic of the carboxyl group, indicates the
incorporation of a minor acrylic acid fraction as expected. Besides, a band at 1460cm is
clearly observed, which can be attributed to the -CH3 and -CH2- deformation of both
monomeric units.74
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Figure 2.2. FTIR-ATR spectrum of the 3D PNIPAAm-co-PAAc polymer matrix on the sensing
surface.

The thickness of the PNIPAAm-co-PAAc polymer layer under hydrated and dehydrated
condition was determined by AFM using the aforementioned manner.75 Figure 2.2(A)

35

shows the morphologies and line profiles of the scratched areas under both conditions,
with the average thickness of each sample determined from the line profiles.

The

hydrated polymer layer displays a thickness of 40.6±3nm, where as the dehydrated
polymer layer exhibited a thickness of 10.1±1nm. Fig. 2.2(B) shows a SEM image in
which AuNPs (bright dots) can be observed along the backbone of the polymer hydrogel,
indicating that AuNPs were successfully embedded in the PNIPAAm-co-PAAc hydrogel
by the linkage with AAc.

Figure 2.3. (A) AFM images of the polymer matrices under hydrated (upper) and dehydrated
(lower) conditions, indicating the swelling-shrinking process. (B) SEM image of the LSPR sensor
coated with AuNPs doped hydrogel thin film.

2.3.2. Optimization of ArsA immobilization conditions
The incubation time required for the binding reaction between ArsA and polymer matrix
is a critical parameter that determines the performance of our kinetics sensor. Insufficient
incubation time causes low coverage of ArsA on the surface and leads to lower
sensitivity, whereas over-long incubation time may results in multiple layers of ArsA and
leads to blockage of binding sites and lower efficiency. To optimize the time required for
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completeness of the covalent linking, 80µg/mL ArsA solution was injected and past the
PNIPAAm-co-PAAc modified gold sensing surface at various injection rates (5, 10, 15,
20, 25, 30, 35µL/min). LSPR angle shift was used to evaluate the surface coverage. The
experiment was repeated 3 times with each injection rate. For each injection rate, 3
measurements were averaged as shown in Figure 2.3(A) with standard deviation. This
study found that ArsA immobilization with a sample injection rate of 20µL/min or slower
exhibited a stable response demonstrating the complete interaction between ArsA and
PNIPAAm-co-PAAc.

Therefore, we employed optimized sample injection rate of

20µL/min for further immobilization and analysis.

In order to evaluate the amount of ArsA ATPase immobilized on the surface of the 3D
polymer matrix, we investigated the LSPR response to different concentrations of ArsA
injections. Initially, polymer modified LSPR chips were activated using 75mM EDC and
15mM NHS in MOPS buffer. Following activation, each activated sensor was employed
to react with different concentrations of ArsA solution (10, 20, 30, 40, 50, 60, 70,
80µg/mL) at an injection rate of 20µL/min. The experiment was repeated 3 times with
each ArsA concentration. The resulting averaged LSPR response for each concentration
was plotted against the corresponding concentration of ArsA with standard deviation as
shown in Figure 2.3(B). It is evident that the amount of ArsA ATPase bound to the
sensing surface reaches a maximum at 50µg/mL and remains constant at all concentration
beyond. As a result, we employed 50µg/mL as an optimum concentration for further
binding study.
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Figure 2.4. Optimization of immobilization conditions: (A) ArsA immobilization on the 3D
polymer coated surface with different injection rate (5, 10, 15, 20, 25, 30, 35µL/min). Maximum
SPR angle shift is plotted versus responding injection rate. (B) Different concentration of ArsA
(10, 20, 30, 40, 50, 60, 70, 80µg/mL) immobilization on the 3D polymer coated LSPR sensor
with optimal injection rate (20µL/min). Maximum SPR angle shift is plotted versus ArsA
concentration.

2.3.3. ArsA and As(III) interaction
Sensitivity study was first performed with chips coated by AuNPs doped polymer layer.
Prior to the binding test for each different concentrations of arsenite, ArsA was
immobilized onto the activated carboxylic groups by the aforementioned protocol. Then,
three different concentrations of arsenite (8mM, 4mM, 2mM) were dosed separately with
an injection rate of 20µL/min. Figure 2.4(a) shows the LSPR response to the injection of
each arsenite sample. When the test solution was introduced at ~50s, ~620s and ~1100s,
a blue shift of 25.8mDeg, 19.1mDeg and 16.5mDeg were observed corresponding to the
introduction of 8mM, 4mM and 2mM arsenite sample, respectively. The 2D AuNPs
structure was not expected to induce as much LSPR enhancement as the 3D AuNPs
doped polymer matrix according to our previous mentioned theory.

Therefore, we

repeated the binding experiment with chips decorated by 2D AuNPs structure. Figure
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2.4(b) indicates that a blue shift of 3.7mDeg, 2.9mDeg and 2.4mDeg were recorded in
response to the same concentration gradients of arsenite. The above experiments were
repeated 4 times for both 3D and 2D LSPR sensors. Similar results were observed (data
not shown). As a result, the signal enhancement of the 3D polymer matrix was calculated
to be about 6.8 fold (averaged from 4 repeated comparisons). This sensitivity increase
can be attributed to the unique swelling-shrinking property of the PNIPAAm-co-PAAc
hydrogel, yielding a greater capacity for ArsA immobilization than that of the 2D AuNPs
chip (Scheme 2.1.).

Figure 2.5. SPR sensorgrams for the covalently immobilized ArsA interacting with As(III)
obtained with (a) 3D AuNPs doped polymer coated sensor and (b) 2D AuNPs structure
modifiedsensor.
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We expected larger enhancement from the 3D polymer matrix since the previous
mentioned AFM measurements demonstrate that the thickness of the hydrated polymer is
40.615nm, indicating an ideal capacity increase of 180 fold for ArsA (63kDa, a=73.34,
b=75.64, c=223.42Å) compared to the ArsA monolayer formed on the 2D chip. One
possible explanation for this discrepancy is the heterogeneous distribution of carboxylic
groups during the random copolymer reaction resulting in a lack of available binding
sites for ArsA. We also suspect that the injected ArsA bound to the surface of the
polymer matrix has blocked the access of the unbound ArsA ATPase to binding sites
inside the polymer matrix.

2.3.4. Kinetics study of ArsA-As(III) binding
ArsD is a metallochaperone that delivers As(III), as well as other trivalent metalloids, to
the ArsA ATPase. Previous studies have shown that interaction with ArsD increases the
affinity of ArsA for As(III), conferring resistance to environmental concentrations of
arsenic.76 However, there is a lack of research on the binding affinity of ArsA for ArsD
till now. Based on measurements on the effect of the As(III) chelator dimercaptosuccinic
acid on the transfer reaction, it is suggested that As(III) transfer is directly channeling
from one protein to the other, rather than dissociating from ArsD and reassociating with
ArsA. Therefore, affinity study between ArsA and ArsD is essential to understanding the
structure of ArsA-ArsD complex and improve understanding of the transfer reaction.

Initially, ArsA was immobilized to the activated carboxylic groups of the polymer as
previously mentioned. Following this, 1% ethanolamine was injected to block the free
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carbonyl groups. ArsD metallochaperone (50µg/mL) was then introduced to the flow
chamber at 20µL/min. For comparison, ArsD was substituted by bovine serum albumin
(BSA) in the negative control experiment. Figure 2.5 shows the LSPR sensorgram for
the ArsA-ArsD interaction study. The binding between ArsA and ArsD (red) results in
an angle shift of 356.2 mDeg, whereas the binding between ArsA and BSA (black) only
results in an angle shift of 45.5 mDeg. The above experiments were repeated 4 times for
both ArsD and BSA binding. Similar results were observed (data not shown). Thus, it is
evident that ArsA is able to specifically bind ArsD without the presence of As(III) and
MgATP. This result is consistent with the direct transfer of As(III) in the ArsA-ArsD
complex.

Figure 2.6. SPR sensorgrams for covalently immobilized ArsA interacting with (red line) ArsD
and (black line) BSA as control.
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2.3.5. Effects of ArsD and MgATP on ArsA-As(III) binding
We have previously shown that ArsD transfers As(III) and Sb(III) to ArsA in the
presence of MgATP.77

Herein, binding kinetics of ArsA-As(III) interaction was

compared using the 3D LSPR sensing platform under MgATP catalytic, ArsD promotion,
and noncatalytic conditions.

ArsA was bound to the 3D LSPR sensing surface using the same manner.

As(III)

samples of 10 different concentrations (0.1-1mM) were prepared in MOPS buffer. First,
ArsA-As(III) binding kinetics was measured without catalysis as a control experiment.
Samples with 0.1-1mM As(III) were injected in 10 min interval between each other to
allow for baseline stabilization.

Following this, ArsA-As(III) binding kinetics

measurement was repeated under the presence of ArsD or MgATP, respectively. The
measurements were repeated 4 times for each condition. SPR angle shift-time curve
(data not shown) was obtained for each measurement in realtime. In this experiment, the
surface interaction [ArsA + As(III) ArsA-As(III)] was measured by the rate of ArsAAs(III) complex production.

Such interaction can be described as a second order

reaction:

by the pseudo-second-order kinetic equation:

where k is a second order rate constant, [A] and [B] are the concentrations of reactants A
and B, respectively.
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In the association phase of the SPR sensorgram, we used the modified pseudo-secondorder kinetic equation to describe the reaction:

where R is the SPR signal at time t, ka is the association rate constant which indicates the
binding affinity between two reactants, [ArsA] and [As(III)] are the concentrations of
ArsA and As(III), respectively. The maximum value of (dR/dt) for each sample was
determined by calculating the maximum slope of the association curve using Matlab.
Linear fitting was utilized to obtain ka since [ArsA] is constant. Figure 2.6(A) shows the
averaged max(dR/dt) for each As(III) concentration with standard deviation. After linear
fitting, ka was calculated to be 1.07M/min with a 0.06 standard error for noncatalytic
ArsA-As(III) interaction. Based on the aforementioned study, interaction with ArsD
increases the affinity of ArsA for As(III). Therefore, association rate constant was also
determined for the ArsA-As(III) interaction under the presence of ArsD in the
environmental buffer and ka was calculated to be 2.79M/min with a 0.41 standard error
using the same method, as shown in Figure 2.6(B). It appears that the max(dR/dt) vs.
As(III) concentration plot fits a quasi-exponential shape under the presence of ArsD,
which does not agree with the linear fitting of our model. Such mismatch can be
attributed to the unexpected change of the surface ArsA concentration. Due to the
comformational and functional similarity between ArsA and ArsD, it is likely that the
ArsD in the flowing buffer affected the binding equilibrium between the surface and
ArsA. Furthermore, ArsA contains two nucleotide binding sites (NBSs) and a binding
site for arsenic, and crystallizes in the presence of As(III) and MgATP.78 Based on these
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structural features, we tested association rate constant under the MgATP catalysis.
Results show that the ka was significantly raised to 16.09M/min with a 0.66 standard
error (Figure 2.6(C)). By comparing these three sets of experiments, it is obvious that the
binding efficiency is significantly raised under the presence of MgATP, indicating that
the activity of the arsenic binding site is dependent on the binding status of the two NBSs
for ATP.79 Based on the result, As(III) transfer occurs only under conditions where ArsA
hydrolyzes ATP, suggesting that ArsD transfers As(III) to an ArsA conformation
transiently formed during catalysis and not simply to the closed conformation that ArsA
adopts when As(III) and MgATP are bound.
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Figure 2.7. Comparison of ArsA-As(III) association rate constant (slope) under the effect of
different binding status. Figure showing: linear fitting curve of the relationship between
maximum binding rate and As(III) concentration under (A) noncatalytic, (B) ArsD bounded and
(C) MgATP catalyzing conditions of ArsA.

2.4. Conclusions
We have demonstrated the fabrication of AuNPs decorated 3D PNIPAAm-co-PAAc
hydrogel modified LSPR sensors. Sensitivity enhancement of 7fold was achieved for
measurement of changes in bulk refractive index using LSPR spectroscopy, compared to
the conventional 2D nanostructural LSPR sensor. Not only can the 3D hydrogel matrix
act as a molecular sponge to increase the analyte absorbing capacity, but it also provides
specificity, tunable size of porous structure and interparticle distance for different
potential applications. Furthermore, we have demonstrated the ability of ArsA ATPase
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specifically bind ArsD metallochaperone without presence of As(III) and MgATP, thus
proving the existence of the structure of ArsA-ArsD complex, which indicates direct
channeling of As(III) from ArsD to ArsA. We also applied the 3D LSPR sensor to study
the binding kinetics of the arsenic detoxifying systems found in E. coli. Results indicates
that transfer of As(III) from ArsD to ArsA is dependent on the binding and hydrolysis of
MgATP.

Overall, this work presents a novel combination of a highly sorbtive polymer with AuNPs
for enhanced sensitive LSPR spectroscopy.

Real-time binding kinetics data were

obtained by the LSPR sensor for further understanding of a biochemical process. The
flexibility of this sensing platform to accommodate different ligands provides a practical
strategy to detection and kinetic study of other biomolecules.
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Chapter 3

Sensing platform upgrade for biomarker studies from a living cell model
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3.1. Introduction
SPR based biosensing has been a very hot topic drawing substantial research interests in
the past decade.

Promising biomedical applications of SPR have also been widely

studied such as detection of binding activity between cells, proteins, DNA and even small
inorganic molecules.80-84 In the previous chapter, a LSPR with enhanced sensitivity for
detecting bindings between proteins and heavy metal molecules was successfully
achieved. However, this sensing platform is only capable for detection of analytes in
solution. An upgraded SPR sensing platform with the ability of direct measurement of
cellular secretion (proteins, DNA, RNA, etc.) from living cells is needed for both
fundamental and clinical research.

The principle of SPR biosensors is the measurement of refractive index changes at a
plane interface between two media with dielectric constants of opposite signs, a dielectric
and a metal, such as gold. SPR can be excited when a wedge of polarized light is
directed towards the glass face of the sensor surface under the condition of total internal
reflection. The resonant angle at which a minimal intensity of reflected light occurs is a
function of the local refractive index at or near the gold surface. Such refractive index
changes associate intimately with the adsorption or desorption of molecules from the
surface, and thus one can expect its great potential in biorecognition measurements.53
This is a newly emerged technique for biomarker detection that is sensitive, fast and
realtime. To date, all previously established SPR based sensing platforms have been
limited to detection of analyte in a prepared sample.19, 85-86 In these strategies, collection
of analytes from cell culture media, purification and pretreatment of analytes are usually
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required for the purposes of cellular exocytosis and cellular signaling pathways studies.8788

These redundant steps are time consuming, and also introduce unpredictable errors to

the experiments.

Therefore, it is desirable to find an alternative method for direct

measurement of secretions from living cells.

Among all types of cellular secretions, biomarkers are no doubt the most significant ones
for clinical, medical and biochemical applications. According to the FDA’s definition,
there are four different types of biomarkers: (1) Prognostic biomarkers are used to
determine the disease progression in a patient; (2) Predictive biomarkers are a baseline
characteristic that indicate the likelihood a specific patient will respond to a given
treatment; (3) Pharmocodynamic biomarkers test the biological response that occurres in
a patient after receiving a particular drug, such as a change in blood pressure or
cholesterol. Drug companies usually test these biomarkers in phase II clinical trials and
submit the results to the FDA; (4) Surrogate endpoints biomarkers are used as a substitute
for a clinical efficacy endpoint.

Biomarker based cancer diagnosis and treatment on the molecular level have emerged
recently.

Compared to traditional antineoplastic solutions, such as chemotherapy,

radiation therapy, and cryosurgery etc., biomarker therapy revealed mild side effects in
clinical studies.89 Biomarkers comprise of cellular molecules such as proteins or nucleic
acids that can be detected in cells, blood, urine, or other body fluids and are overexpressed due to the onset of disease. Proteomic biomarkers are widely involved in the
development of many types of cancer. Like all other types of human cells, cancer cells
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also rely on a constant oxygen supply to maintain their cellular activity. A tumor larger
than a millimeter will starve itself of oxygen and energy unless new blood vessels are
built to provide a supply.

For this reason, many cancer cells employ the normal

processes of angiogenesis in order to build their own blood supply.43

VEGF, a 43 to 46 kDa glycoprotein, is a widely studied angiogenic signal protein
biomarker produced by oxygen-hungry cells to promote the growth of blood vessels.90 It
binds to specialized receptors on the surfaces of endothelial cells and directs them to
build new vessels. Some types of tumor cells produce abnormally large amounts of
VEGF or block the action of angiogenesis inhibitors.

This action is termed as

‘‘angiogenic switch’’, giving the ability of metastasis to the tumor, since a custom-made
blood supply can be constructed wherever new tumors begin to grow.44

In this work, we report a new concept of a SPR biosensing system for realtime VEGF
secretion study. A novel design by integrating a mini cell culture module to the SPR
system will be introduced. Unlike the traditional configuration of SPR systems for
biomarker detection, living cells are cultured on the ceiling of a customized SPR flow
cell chamber, and biomarker secretion from cells is rapidly monitored by an immune SPR
sensing device (Scheme 3.1). As a model system, the SKOV-3 ovarian cancer cell line is
used to demonstrate VEGF secretion lifetime measurement.

To the best of our

knowledge, this new SPR based biosensing strategy for direct measurement of biomarker
from living cells has not been reported previously.
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Scheme 3.1 Configuration of the SPR based biosensor integrating a mini cell culture module for
direct measurement of biomarker from living cells.

3.2. Experimental
3.2.1. Materials
Human ovarian carcinoma cell line (SKOV-3), McCoy's 5A medium, and fetal bovine
serum were purchased from American Type Culture Collection (Manassas, Virginia). 6well tissue culture plates, d-poly coverslips, and formalin were purchased from Fisher
Scientific. VEGF, monoclonal anti-VEGF antibody, KREB’s buffer and Penicillin were
obtained from Sigma-Aldrich (St. Louis, MO). MUA was purchased from Asemblon
(Redmond, WA). Calcium Ionophore (A23187) was purchased from Acros Organic
(New Jersey). EDC and NHS were obtained from Alfa Aesar (WardHill, MA). Protein
G was purchased from Fisher Scientific (Waltham, MA). All reagents and solvents were
used as received unless otherwise stated.
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3.2.2. Instrumentation
A BI-2000 SPR instrument purchased from Biosensing Instrument (Tempe, AZ) was
used for data collection. A 670nm wave length laser with a 72.2° incident angle was
employed as the light source of the SPR instrument.

The gold SPR chip

(20mm×20mm×1mm) is a BK7 glass slide coated with a 45nm layer of gold over a 5nm
layer of chromium.

A 3-5 µL drop of index matching fluid (World Precision

Instruments, Inc., FL) was to be applied between the glass face of the chip and the prism
with care so that no air bubbles were trapped at the interface.

Following this, a

biocompatible PDMS microfluidic injection chamber gasket with a 5mm×1.7mm×125µm
channel was clamped to the gold face of the chip. A dual syringe pump was attached to
the injection chamber allowing both sample and reference buffer flow through the
sensing surface.

An Olympus IX81 fluorescence microscopy (Japan) with a 20x

objective was employed for cell fluorescent imaging. A CCD camera was used to
capture the signals and the images were software-merged with pseudo color.

3.2.3. Surface treatment for SPR flow chamber
SPR flow chamber gasket (Figure 3.1) was detached from the SPR flow cell. Several
drops of 0.1% w/v gelatin solution made by boiling distilled water were applied onto the
PDMS gasket to cover the whole surface. The gasket was then dried for 12h in a
biological fume hood to prevent contamination. A cell culture petri dish and a uncoated
PDMS gasket were also prepared as positive and negative control substrates,
respectively.
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Figure 3.1. SPR Flow Cell and Flow Chamber Gasket.

3.2.4. Human cell culture
SKOV-3 cells were cultured in McCoy's 5A medium added with 1% penicillin and 10%
fetal bovine serum, and kept in a 37°C cell incubator with a humidified atmosphere of
5% CO2 and 95% air. 200,000 cells were seeded on the gelatin coated SPR flow chamber
gasket and kept in a 6-well tissue culture plates with cell culture media for 48h before
each experiment. The same cell culture was repeated on an uncoated PDMS gasket and a
tissue culture plate as control experiments.

3.2.5. Cell stain and fluorescent imaging
200 μM MitoTracker Red CMXRos dye stock solution and the 1.0 mM Hoechst 33342
dye were diluted into HBSS or appropriate cell medium with serum. The concentration
for MitoTracker Red CMXRos dye is 10-50 nM; The concentration for Hoechst 33342
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dye is 1.0 μg/mL. Both dyes may be combined in a single staining solution. Then apply
a sufficient amount of labeling solution to cover cells adhering to substrates. Incubate for
15 minutes at 37°C. When labeling is complete, remove the labeling solution and wash
cells twice in cell medium. Labeled cells will then be fixed with 4% formaldehyde for 15
minutes at 37°C, followed by washes in buffer and staining with any additional
counterstains.

The substrates were then removed and mounted on glass microslides with antifade
reagent/mounting medium mixture. Then, the specimens were observed by fluorescence
microscopy (Olympus IX81, Japan) with a 20x objective. The fluorescence was imaged
at Hoechst channel (nucleus stain dye, ex/em: 358/461 nm), and λex (570), λem (590 nm)
for mitotracker red. A CCD camera was used to capture the signals and the images were
software-merged with pseudo color. The fluorescence microscope settings were kept the
same throughout the experiment with the exception of the exposure time. The images
were recorded at the same exposure time for Hoechst and MitoTracker Red.

3.2.6. Calibration of SPR for VEGF measurements
A previously reported method was used for immobilization of monoclonal anti-VEGF
antibody on the SPR gold chip.91 Briefly, SPR gold chip will be emerged in 1mM MUA
(ethanol) solution for 12h at 4°C to form a layer of carboxylic groups on the gold surface.
The gold chip will then be washed with copious ethanol and mounted on the SPR system.
Carboxylic groups were then activated with a solution of EDC (75mM) and NHS
(15mM). Following this, an activated SPR chip was immobilized by injecting 50 µg/mL
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protein G solution to capture the Fc portions of the antibody in order to assure proper
antibody orientation.92 50 µg/mL monoclonal anti-VEGF was bounded on top of the
protein G layer as the biorecognition ligand. All injections to the SPR microfluidic
system were performed with a 20 µL/min rate. SPR experiments were performed in
phosphate buffered saline (PBS) as the flowing buffer, and each solution was also
prepared in PBS (pH=7.4) unless otherwise specified.

The sensor calibration was

performed using VEGF samples with 8 different concentrations (0.25, 0.5, 1, 1.5, 2, 2.5,
3, 4 µg/mL). The calibration was repeated 4 times for reproducibility test.

3.2.7. Direct measurement of VEGF from living cancer cells
In order to demonstrate direct measurement of VEGF from living carcinoma cells,
SKOV-3 cells were cultured for 48h on gelatin coated gaskets using the aforementioned
method.

The same functionalization protocol described above will be used for

immobilization of monoclonal anti-VEGF antibody on the SPR sensing chip. The PDMS
flow chamber gasket with SKOV-3 cell culture was then removed from cell culture
media and throughly rinsed with Kreb’s buffer to remove cell culture media and
unattached cells. Following this, the PDMS gasket with cells was mounted on the SPR
flow chamber, and SPR flowing buffer was changed from PBS (pH = 7.4) to Kreb’s
buffer (pH = 7.4) in order to maintain cell viability during experiments. After resuming
the buffer flow, 500µm Ca2+ ionophore (A23187) was injected to induce rapid exocytosis
of VEGF from the SKOV-3 cells. The above VEGF measurement was repeated 4 times.

56

3.3. Results and discussion
3.3.1. Calibration for VEGF
Initially, reproducibility and linearity of the functionalized Au sensing surface were
examined using different concentrations of the VEGF sample. Figure 3.2.A shows the
time resolved SPR spectra in response to VEGF binding (3, 4 µg/mL samples not
shown). VEGF binding can be clearly characterized by the SPR angle shift upon
introduction of the VEGF sample solution. Figure 3.2.B depicts the calibration curve
obtained by a linear fit of SPR response to different concentrations of VEGF samples.
The SPR sensor allows real-time and sensitive VEGF detection within a linear dynamic
range of 0.1-2.5 µg/mL. For each VEGF concenration, the SPR response was determined
by the average of 4 measurements. The maximum value of the inter-assay relative
standard deviations was 13.6% (n = 4). This indicates that our detection strategy offers
an acceptable reproducibility towards the detection of VEGF.
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Figure 3.2. (A: upper) SPR sensor responses to VEGF solution at different concentration levels:
(a) at 0.25µg/mL, (b) at 0.5µg mL, (c) at 1µg/mL, (d) at 1.5µg/mL, (e) at 2µg/mL and (f) at
2.5µg/mL. (B: lower) Calibration curve: the linear relationship between change of SPR angle
shift and VEGF concentration.
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3.3.2. Fluorescent imaging
For the purpose of measuring VEGF secretion directly from living cancer cells, we first
demonstrated cell viability in the SPR flow chamber.

Fluorescent imaging was

performed using a previously reported method in order to examine cell confluency on
each substrate.93 As shown in Figure 3.3, cell counts on the tissue culture plate, gelatin
coated gasket and uncoated gasket are 174, 218 and 76, respectively. Since the gelatin
coated gasket showed significant enhancement of cell attachment compared to the
uncoated gasket, it is a suitable substrate for the living cell experiment in the SPR flow
chamber.
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Figure 3.3. Fluorescence images of SKOV-3 cell culture on: (upper) petri dish, (middle) gelatin
coated PDMS and (lower) uncoated PDMS.

3.3.3. Direct measurement of VEGF from living cancer cells
The time resolved SPR response upon Ca2+ ionophore injections is shown in Figure 3.4.
Each arrow in the figure indicates an injection of Ca2+ ionophore. A 87 ± 6mDeg (n=4)
SPR angle shift was observed after the first injection (data not shown for repeated
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measurements). However, the following two injections did not induce obvious angle
shift. It seems that all intracellular VEGF was released during the first stimulation.
According to our calibration curve for different concentrations of the VEGF samples,
SKOV-3 cells released about 1µg/mL VEGF during the stimulation.94

Figure 3.4. SPR sensor responses to living SKOV-3 cells secretion stimulated by injections of
500µm Ca2+ ionophore (A23187). Each arrow indicates an injection of Ca2+ ionophore.

3.3.4. Cell number study
We also performed a cell number study to investigate the relationship between the
amount of VEGF secretion and total cell number. Different numbers of cells (50000,
100000, 200000) were seeded on three similar PDMS gaskets and cultured under the
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same conditions as previously mentioned. After 48 h, the cell numbers reached 80000,
160000 and 320000, respectively. SPR measurements were then performed 4 times for
each of the 3 samples with different cell numbers. Figure 3.5 shows the SPR responses to
induced VEGF secretion from different numbers of cells (data not shown for repeated
measurements). SPR angle shift for each cell number group was determined by the
average of 4 repeated measurements. From each averaged SPR angle shift, we can obtain
the VEGF concentration secreted by the 3 different cell number groups. The SPR flow
chamber volume is 2 mL. Finally, we calculated the amount of VEGF released from
each cell to be 0.0137 ± 0.0012 pg (n=12) by averaging the VEGF singal cell release
amount yielded for each of the 3 cell number groups. Due to the capacity limitation of
our SPR flow chamber, the sample of 320000 cells had reached 100% confluency inside
the chamber. Therefore, we were not able to further investigate the VEGF release
amount from a larger group of SKOV-3 cells. However, this sensing platform has
provided a strategy for accurate prediction of carcinoma cell number.
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Figure 3.5. SPR sensor responses to stimulated VEGF secretion from groups of cells with
different cell numbers. VEGF secretion from (a) 80000 cells induced 43.4±5.7 mDeg (n=4) SPR
angle shift; (b) 160000 cells induced 100.6±8.9 mDeg (n=4) SPR angle shift; (c) 320000 cells
induced 214.2±15.1 mDeg (n=4) SPR angle shift.

3.4. Conclusions
In conclusion, this work demonstrates the new concept of a SPR biosensor for biomarker
study. On the basis of integration of a mini cell culture system within the traditional SPR
sensing platform, this biosensor is capable of direct measurement of VEGF biomarker
secretion from living SKOV-3 carcinoma cells. Because the configuration of this SPR
biosensor mimics the in vivo microenvironment of the VEGF signaling pathway, this
platform possesses great potential on cellular signaling pathways study and antineoplastic
drug development. By modifying the surface functionalization of the SPR assay, this
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biosensor might open up new horizons for detection and analysis of biomarker from
living cells and tissue for different diseases.
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Chapter 4

Study of drug regulation on the VEGF binding kinetics with a living cell model
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4.1. Introduction
We have constructed an upgraded SPR biosensor with the ability of direct detection of
disease biomarkers from living cell models in the previous chapter. This sensing strategy
also possesses the potential of drug regulation study with living cell models. In this
chapter, we will further investigate the feasibility of performing antineoplastic drug
regulation studies on the cellular level by SPR biosensors.

For the past decade, cancer ranked the second leading cause of death in the United States.
In 2012, a total of 1,638,910 new cancer cases and 577,190 deaths from cancer occurred
in the United States alone.95

According to the defination of the American Cancer

Society, cancer is the general name for a group of more than 100 diseases. Although
there are many kinds of cancer, all cancers start because abnormal cells grow out of
control.96-99 Cancer types can be grouped into 5 main categories: (1) Carcinoma - cancer
that begins in tissues or in the skin that cover internal organs; (2) Sarcoma - cancer that
begins in connective or supportive tissue such as: bone, muscle, cartilage, fat, blood
vessels, etc.; (3) Leukemia - cancer that starts in blood-forming tissue such as the bone
marrow and causes large numbers of abnormal blood cells to be produced and enter the
blood; (4) Lymphoma and myeloma - cancers that begin in the cells of the immune
system; (5) Central nervous system cancers - cancers that begin in the tissues of the brain
and spinal cord.100-102 Although some cancers, like leukemia, lymphoma and myeloma,
rarely form tumors; in most cases, cancer cells form a tumor. A tumor larger than a
millimeter will starve itself of oxygen and energy unless new blood vessels are built to

66

provide supplies.103-104 A process known as angiogenesis is found to be involved in
building new blood vessels for many types of cancer.

Angiogenesis is a complex process defined as the growth of new blood vessels from
existing vessels.105-106 Normal embryogenesis and embryonic development occurs under
normal physiological conditions in adults, whereas angiogenesis occurs during tissue
repair, ovulation and endometrial regulation.107-108 Mediators of angiogenesis such as
VEGF stimulate endothelial cells to secrete proteases and plasminogen activators. Cells
will then migrate, proliferate and eventually differentiate to form a new lumen vessel.109
Many pathological conditions involve or mimic the angiogenic process, such as:
atherosclerosis, rheumatoid arthritis, diabetes, heart disease and solid tumor growth.110 It
is well established that tumor progression requires angiogenesis for blood and oxygen
supply. Cancers switch on angiogenesis by breaking the balance between production of
angiogenic stimulus and inhibitor factors.43, 111-112 The angiogenesis process consists of
several steps: (1) Angiogenic factor production; (2) Release of angiogenic factor; (3)
Endothelial cell receptor binding and activation; (4) Endothelial cells proliferation; (5)
Membrane formation and stabilization.113 VEGF is a very common angiogenic factor
and VEGF receptor (VEGFR) is a very common endothelial cell receptor.

VEGF-

VEGFR binding process is the key point of neovascularization.114-115 Targeting the
endothelial cells receptor binding and activation process is a potential strategy for cancer
repression. However, many questions about the VEGF signaling pathway remains not
clearly understood.
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The VEGF family and its receptors include: (1) VEGF-A for endothelial cells migration
and mitosis, creation of blood vessel; (2) VEGF-B specifically for myocardial tissue; (3)
VEGF-C for lymphangiogenesis; (4) VEGF-D for the development of lymphatic
vasculature surrounding lung bronchioles; (5) PlGF for vasculogenesis, also involved in
cancer; and VEGFR-1, VEGFR-2, VEGFR-3 (Scheme 4.1).90 Among these members,
VEGF-A and VEGFR-1 are most widely involved in different types of cancer.116

Scheme 4.1. Schematic diagram of the relationships between VEGF and VEGF receptors.

There are more than 100 antibodies currently approved by FDA or under development for
cancer therapy by regulating VEGF-VEGFR binding interaction.117-118

One such

approved antibody is bevacizumab, a humanized anti-VEGF monoclonal antibody
generated by engineering the VEGF binding residues of a murine neutralizing antibody
into the framework of the consensus human immunoglobulin G1 (IgG1).89,

119

Bevacizumab recognizes VEGFR-1 (flt-1) and VEGFR-2 (KDR) receptors and thus binds
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and neutralizes all biologically active forms of VEGF that interact with these receptors.120
The efficacy of bevacizumab against various cancer types has been demonstrated in
several clinical studies (Table 4.1).121-125

Indication

Sample

Conclusions

Number
Colorectal

104

Cancer

Bevacizumab combined with chemotherapy was well
tolerated and may be effective in increasing response rates
and prolonging time to disease progression in patients with
metastatic colorectal cancer

Non-small
cell

99

lung

The

addiction

of

bevacizumab

(15

mg/kg)

to

carboplatin/paclitaxel chemotherapy increased time to

cancer

disease progression and improved response rates in patients
with advanced non-small cell lung cancer

Breast cancer

28

Bevacizumab was well tolerated and might offer some
benefit in patients with solid tumors in progression

Other Cancer

12

Bevacizumab combined with chemotherapy was safe and
may be effective in patients with advanced cancer

Table 4.1. Summary of bevacizumab clinical studies.

Although there are numerous clinical studies and trials on the drug efficacy of
bevacizumab on cancers, only a few fundamental studies on the interaction between this
widely used drug and VEGF have been reported.20,
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126-129

Kinetics study on VEGF-

bevacizumab binding helps elucidate the fundamental mechanism of bevacizumab
inhibition to angiogenesis. Tranditional techniques to measure the binding kinetic of
VEGF and bevacizumab are Western blot and ELISA.130-131

These techniques can

monitor cells only at a single time point and therefore do not allow for real-time
monitoring.

Another previous study has shown an in vitro real-time monitoring of

VEGF-bevacizumab binding using SPR.20 However, the experimental condition was not
similar to the in vivo VEGF signaling pathway since it was performed with the
commercial VEGF solution.

In our previous studies, we have successfully demonstrated real-time monitoring VEGF
expression from living human ovarian carcinoma cells using SPR.132 By intergrating a
mini cell culture system into the SPR flow system, we were able to maintain live cell
culture on the ceiling of the SPR flow chamber in order to realize VEGF measurements
from living cells. In this study, we have measured and compared the binding affinity of
VEGF to VEGFR and VEGF to bevacizumab. Finally, we employed this living cell
sensing platform to mimic the in vivo condition of the VEGF signaling pathway.
Competitive binding to VEGF between VEGFR and bevacizumab was monitored in realtime.

The results have shown significant blockage of VEGF-VEGFR binding by

bevacizumab.

70

4.2. Experimental
4.2.1. Materials
Bevacizumab (200 mg) were friendly donated by Genentech, Inc. (San Francisco, CA)
VEGF, VEGFR, KREB’s buffer and Penicillin were obtained from Sigma-Aldrich (St.
Louis, MO).

SKOV-3 cells, McCoy's 5A medium, and fetal bovine serum were

purchased from American Type Culture Collection (Manassas, Virginia). 6-well tissue
culture plates, d-poly coverslips, and formalin were purchased from Fisher Scientific.
MUA was purchased from Asemblon (Redmond, WA). Calcium Ionophore (A23187)
was purchased from Acros Organic (New Jersey). EDC and NHS were obtained from
Alfa Aesar (WardHill, MA). Protein G was purchased from Fisher Scientific (Waltham,
MA). All reagents and solvents were used as received unless otherwise stated.

4.2.2. Instrumentation
A BI-2000 SPR instrument purchased from Biosensing Instrument (Tempe, AZ) was
used for data collection. A 670nm wave length laser with a 72.2° incident angle was
employed as the light source of the SPR instrument.

The gold SPR chip

(20mm×20mm×1mm) is a BK7 glass slide coated with a 45nm layer of gold over a 5nm
layer of chromium. A biocompatible PDMS microfluidic injection chamber gasket with
a 5mm×1.7mm×125µm channel was clamped on top of the gold face of the chip. A dual
syringe pump was attached to the injection chamber allowing both sample and reference
buffer flow through the sensing surface. An Olympus IX81 fluorescence microscopy
(Japan) with a 20x objective was employed for cell fluorescent imaging. A CCD camera
was used to capture the signals and the images were software-merged with pseudo color.
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4.2.3. SPR flow chamber surface pre-treatment and human cell culture
SPR flow chamber gasket was detached from the SPR flow cell. Several drops of 0.1%
w/v gelatin solution made by boiling distilled water were applied onto the PDMS gasket
to cover the whole surface. The gasket was then dried for 12h in a biological fume hood
to prevent contamination.133 A cell culture petri dish and a uncoated PDMS gasket were
also prepared as positive and negative control substrates, respectively.

SKOV-3 cells were cultured in McCoy's 5A medium added with 1% penicillin and 10%
fetal bovine serum, and kept in a 37°C cell incubator with a humidified atmosphere of
5% CO2 and 95% air. 200,000 cells were seeded on the gelatin coated SPR flow chamber
gasket and kept in a 6-well tissue culture plates with cell culture media for 48h before
each experiment. The same cell culture was repeated on an uncoated PDMS gasket and a
tissue culture plate as control experiments.

4.2.4. Cell stain and fluorescent imaging
We diluted 200 μM MitoTracker Red CMXRos dye and the 1.0 mM Hoechst 33342 dye
stock solutions into cell medium with serum. The concentration for MitoTracker Red
CMXRos dye is 10-50 nM; The concentration for Hoechst 33342 dye is 1.0 μg/mL. Both
dyes may be combined in a single staining solution. A sufficient amount of labeling
solution was then applied to cover cells adhering to substrates followed by incubation for
15 minutes at 37°C. After that, the labeling solution was removed and cells were washed
twice in the cell medium. Labeled cells will then be fixed with 4% formaldehyde for 15
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minutes at 37°C, followed by washes in buffer and staining with any additional
counterstains.

The substrates were then removed and mounted on glass microslides with antifade
reagent/mounting medium mixture. Then, the specimens were observed by fluorescence
microscopy (Olympus IX81, Japan) with a 20x objective. The fluorescence was imaged
at Hoechst channel (nucleus stain dye, ex/em: 358/461 nm), and mitotracker red channel
(ex/em: 570/590 nm). A CCD camera was used to capture the signals and the images
were software-merged with pseudo color. The fluorescence microscope settings were
kept the same throughout the experiment with the exception of the exposure time. The
images were recorded at the same exposure time for Hoechst and MitoTracker Red.

4.2.5. Preparation of SPR gold sensing surface
A similar method reported in our previous study was used for surface modification of the
SPR gold chip.132 Briefly, SPR gold chip will be emerged in 1mM MUA (ethanol)
solution for 12h at 4°C to form a layer of carboxylic groups on the gold surface. The
gold chip will then be washed with copious ethanol and mounted on the SPR system.
Carboxylic groups were then activated with an injection of EDC (75mM) / NHS (15mM)
solution. All injections to the SPR microfluidic system in this study were performed with
a 20 µL/min rate. Surface modification and immobilization experiments were performed
in PBS as the flowing buffer, and each solution was also prepared in PBS (pH=7.4)
unless otherwise specified.
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4.2.6. Comparison of VEGF-VEGFR and VEGF-bevacizumab binding kinetics
In order to demonstrate the drug efficacy of bevacizumab, binding affinity of VEGFVEGFR and VEGF-bevacizumab interactions was measured and compared. Following
the surface modification of the SPR gold chip, an activated SPR chip was immobilized by
injecting 50 µg/mL protein G solution to capture the Fc portions of the bevacizumab
antibody in order to assure proper antibody orientation. 30 µg/mL bevacizumab was then
bounded on top of the protein G layer. Another SPR chip was immobilized by direct
injection of 30 µg/mL VEGFR onto the activated surface. 2 µg/mL VEGF was injected
to the flow chamber after surface functionalization. SPR sensorgram was collected by
Biosensing Instrument SPR Control Program running on a PC.

4.2.7. Drug regulation study on VEGF-VEGFR binding
A biomimic system was constructed to evaluate the bevacizumab drug regulation on the
VEGF signaling pathway. VEGFR was immobilized on the SPR gold sensing surface by
aforementioned method.

The flowing PBS buffer was paused once VEGFR was

immobilizaed. The PDMS flow chamber gasket used for surface immobilization (no
cells) was removed.

The PDMS flow chamber gasket with SKOV-3 cell culture was then removed from cell
culture media and throughly rinsed with Kreb’s buffer to remove cell culture media and
unattached cells. Following this, the PDMS gasket with cells was mounted on the SPR
flow chamber, and SPR flowing buffer was changed from PBS (pH = 7.4) to Kreb’s
buffer (pH = 7.4) in order to maintain cell viability during experiments. After resuming
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the buffer flow, 500µm Ca2+ ionophore (A23187) was injected to induce rapid exocytosis
of VEGF from the SKOV-3 cells. We added 30 µg/mL bevacizumab to the flowing
buffer to capture the VEGF secretion. Therefore, we have built an in vitro system to
mimic the VEGF-VEGFR release, transportation, binding processes to monitor the
bevacizumab drug regulation in real-time (Scheme 4.2).

Scheme 4.2. Schematic illustration of the biomimic system for bevacizumab drug regulation
study.

75

4.3. Results and discussion
4.3.1. Optimization and calibration for surface concentration of bevacizumab
In order to determine the optimal dose of bevacizumab for this study, we investigated the
SPR response to different concentrations immobilized on the gold sensing surface.
Initially, 50 µg/mL protein G solution was injected to the activated SPR chip followed by
injection of a certain concentration of bevacizumab (5µg/mL, 10µg/mL, 30µg/mL,
50µg/mL, 70µg/mL). Three gold chips were prepared for each concentration. 3µg/mL
VEGF was then injected to pass through the sensing surface. The SPR measurement was
repeated 3 times for each bevacizumab concentration. Figure 4.1 shows the results from
one set of measurements.

The resulting SPR response for each bevacizumab

concentration was plotted against time (70µg/mL data not shown). It is evident that the
amount of VEGF bound to the 50µg/mL bevacizumab sensing surface did not show a
significant difference than the amount of VEGF bound to the 30µg/mL bevacizumab
sensing surface (Figure 4.2). This observation can be attributed to two possible reasons:
(1) 30µg/mL is the saturation concentration of bevacizumab on the surface or (2) 3µg/mL
VEGF injection can be completely captured by 30µg/mL surface bound bevacizumab.
Our previous study showed that even SKOV-3 cells reached 100% confluency in the SPR
flow chamber, the VEGF release did not reach 3µg/mL. As a result, we employed
30µg/mL as the maximum concentration of bevacizumab for further binding studies.
Linear responses of bevacizumab-VEGF binding are obtained between 5µg/mL and
30µg/mL of surface bound bevacizumab concentrations.

76

Figure 4.1. SPR response to 3µg/mL VEGF for each surface bound bevacizumab concentration:
5µg/mL (red), 10µg/mL (blue), 30µg/mL (purple), 50µg/mL (green).
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Figure 4.2. Calibration curve: the linear relationship between SPR baseline shift and the surface
concentration of bevacizumab (n=3).

4.3.2. Specificity study of VEGF-bevacizumab binding
Bevacizumab is a humanized anti-VEGF monoclonal antibody generated by engineering
the VEGF binding residues of a murine neutralizing antibody into the framework of the
human IgG. Therefore, it is only expected to bind with VEGF specifically.134 Any nonspecific binding to other biomolecules is going to affect the efficacy of this drug. We
have already demonstrated the affinity and reproducibility of VEGF-bevacizumab
binding in the previous experiment. In this experiment, we further investigated the
specificity of the VEGF-bevacizumab interaction. VEGF-VEGFR binding and activation
is the most important step of the angiogenesis process, which is also the target of most
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angiogenesis regulation therapy strategies, including bevacizumab. Thus it is crucial to
investigate the interaction between bevacizumab and VEGFR. Similarly, a bevacizumab
layer was formed on the activated SPR gold surface by injecting 10µg/mL bevacizumab.
Following this, 3µg/mL VEGF and VEGFR were injected and passed the two
bevacizumab covered gold chips, respectively. As shown in Figure 4.3A, a 25.1mDeg
baseline shift was observed on the SPR sensorgram due to the VEGF-bevacizumab
binding. However, no significant baseline shift was detected for VEGFR-bevacizumab
interaction (Figure 4.3B).

The results indicate that bevacizumab regulates the

angiogenesis process by blocking the active binding site on VEGF. The specificity study
was then repeated for 3 times. Similar results were observed.
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Figure 4.3. (A) SPR sensorgram of surface bound bevacizumab interacting with VEGF. Inset:
enlarged sensorgram of the response upon VEGF binding.
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Figure 4.3. (B) SPR sensorgram of surface bound bevacizumab interacting with VEGFR. Inset:
enlarged sensorgram of the response upon VEGFR binding.

4.3.3. Study of SKOV-3 cell viability in the SPR flow chamber
For the purpose of constructing the VEGF signaling pathway biomimic system for the
drug efficacy study, we first demonstrated cell viability in the SPR flow chamber.
Fluorescent imaging was performed using the aforementioned method in order to
examine cell confluency on each type of substrate. As shown in Figure 4.4, the cell
confluency on tissue culture plates and gelatin coated gaskets both reached 100%,
whereas the cell confluency on uncoated gaskets only reached 60%. Gelatin coated
gaskets showed significant enhancement of cell attachment compared to uncoated
gaskets. Therefore, it is a suitable substrate for living cell experiments in the SPR flow
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chamber.

Figure 4.4. Fluorescent images of SKOV-3 cells at Hoechst channel, MitoTracker Red channel
and merged images on different type of substrates: petri dishs (exposure time 400ms), gelatin
coated gaskets (exposure time 200ms) and uncoated gaskets (exposure time 200ms).

4.3.4. Binding kinetics study of VEGF-VEGFR and VEGF-bevacizumab interactions
We have previously shown the binding affinity of VEGF-bevacizumab interaction.
Herein, binding kinetics of the VEGF-bevacizumab interaction was compared to that of
the VEGF-VEGFR interaction using the biomimic sensing platform.

Initially, bevacizumab was immobilized on the SPR gold sensing surface using the
aforementioned protocol. Following this, 2µg/mL VEGF solution was injected to pass
the sensing surface. A similar experiment was then performed with VEGFR immobilized
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on the SPR gold sensing surface.
reproducibility test.

Both experiments were repeated 4 times for

The SPR sensorgram of the responses on VEGF binding to

bevacizumab (blue) and VEGFR (red) is shown in Figure 4.5 (data not shown for
repeated measurements).

Figure 4.5. SPR sensorgram of VEGF binding response to bevacizumab (blue line) and VEGFR
(red line).

A modified equation of a previous reported pseudo-first-order kinetic equation135 was
used to determine the association rate constants:

where R is the SPR signal at time t, ka is the association rate constant which indicates the
binding affinity between two reactants, [VEGF] and [ligand] are the concentration of
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VEGF and the surface bound binding ligand (bevacizumab or VEGFR), respectively.
The maximum value of (dR/dt) for each sample was determined by calculating the
maximum slope of the association curve using Matlab. The weight concentration of
VEGF was converted to molar concentration (47.6nM). The concentration of the surface
bound bevacizumab is 30µg/mL (201.3nM). As shown in Figure 4.5, the maximum slope
of the VEGF-bevacizumab binding curve was calculated to be 0.91±0.04 (n=4). Thus the
ka for bevacizumab is 9.5±0.4×1013 M-2 (n=4). Similarly, the concentration of the surface
bound VEGFR is 30µg/mL (166.7nM), the maximum slope of the VEGF-VEGFR
binding curve was calculated to be 0.43±0.01 (n=4). Therefore the ka for VEGFR is
5.4±0.2×1013 M-2 (n=4). We also obtained the binding affinity information for both
interactions from Figure 4.5 by measuring the SPR baseline shift upon VEGF binding.
VEGF-bevacizumab binding induced a 92.7±4mDeg (n=4) baseline shift, whereas
VEGF-VEGFR binding induced a 60.2±3mDeg (n=4) baseline shift. All aforementioned
calculations were obtained by the average of 4 repeated measurements. These results
indicate that bevacizumab captures VEGF with a higher rate and affinity compared to
VEGFR.20

4.3.5. Bevacizumab drug regulation study on VEGF-VEGFR interaction
According to the aforementioned protocol, the drug efficacy of bevacizumab was
evaluated using the VEGF signaling pathway biomimic system, as shown in Figure 4.6.
Briefly, VEGFR was immobilized on the SPR gold sensing surface.

PDMS flow

chamber gasket with SKOV-3 cell culture was mounted on top of the sensing surface.
We employed pure Kreb’s buffer and Kreb’s buffer with 30 µg/mL bevacizumab as the
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SPR flowing buffers for the control experiment and the drug regulation experiment,
respectively. Ca2+ ionophore (A23187) was used to stimulate rapid exocytosis of VEGF
from the SKOV-3 cells. Both the control experiment and the drug regulation experiment
were repeated 4 times under similar condition. In Figure 4.6, the red line depicts the SPR
response of VEGF exocytosis binding to VEGFR on the sensing surface (control
experiment). The peak between ~50s and ~250s can be attributed to the refractive index
change induced by the Ca2+ ionophore (A23187) passing through the sensing surface.
Following the plateau, the baseline is stablized at 103.7±8.4mDeg (n=4). This SPR
baseline shift indicates that VEGF released from SKOV-3 cells has bound to the VEGFR.
The blue line depicts the SPR response of VEGF exocytosis binding to surface VEGFR
under the regulation of bevacizumab (drug regulation experiment). By comparing this
data to the control experiment, the SPR base line has dropped by 82.5±9.6mDeg (n=4)
after the Ca2+ ionophore (A23187) stimulation.

We anticipate this sudden drop of

baseline is due to the surface refractive index decrease caused by the fast binding
between VEGF and bevacizumab in the flowing buffer. However, further experiments
are needed to confirm this assumption. Following the plateau, the baseline is slowly
increasing towards the original position, since the VEGF exocytosis was being carried
away from the sensing surface. No significant baseline increase was observed in this
experiment, which indicates that the VEGF-VEGFR pathway was successfully blocked
by bevacizumab in the flow chamber. The amount of VEGF bound to VEGFR was
significantly decreased under the regulation of bevacizumab.136
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Figure 4.6. SPR response of VEGF (SKOV-3 cells released) – VEGFR interaction (red line) and
VEGF (SKOV-3 cells released) – VEGFR interaction under bevacizumab regulation (blue line) in
the biomimic system.

4.4. Conclusions
In this study, we have constructed a biomimic system for the VEGF-VEGFR signaling
pathway in SPR and investigated its potential application on antineoplastic drugs
development. To the best of our knowledge, this is the first report showing direct and
real-time measurements of drug effect to the VEGF-VEGFR signaling pathway on living
carcinoma cells. SKOV-3 cells and the bevacizumab antibody were used as the cell
model and the drug model for the evaluation of the strategy. SPR exhibits excellent
sensitivity and linear dynamic range towards VEGF and bevacizumab interactions.
SKOV-3 cells were incubated in the modified SPR flow chamber for the drug efficacy
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study.

VEGF-bevacizumab binding showed a higher association rate constant and

binding affinity than VEGF-VEGFR binding. The bevacizumab drug regulation study
reveals successful blockage of VEGF-VEGFR binding and activation process. We have
outlined a highly sensitive and simple strategy for the direct and real-time measurements
of bevacizumab drug efficacy to the VEGF-VEGFR signaling pathway on living SKOV3 cells. It is hopeful that a similar strategy may be employed to develop and evaluate
other type of medicine.
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Chapter 5

Conclusions and Future Work
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5.1. Conclusions
This dissertation demonstrates real-time, direct and sensitive LSPR based biosensors for
biomolecular binding kinetics measurements.

We have achieved a LSPR sensing

platform for the detection of small heavy metal molecule bindings. The performance of
this sensor was evaluated on the study of arsenic detoxification pathway of E. coli. We
also successfully incorporated a mini cell culture system into the flow chamber of the
SPR based biosensors. This novel feature enables the in vitro detection of biomarkers
from living cells.

Following this, the SPR based biosensors with the capability of

biomarker measurements from living cells were employed on the drug regulation study of
the VEGF signaling pathway in cancer cells.

Chapter 1 introduces the objectives, the background and literature review on the
dissertation topic. Three specific aims of this dissertation are also presented.

Chapter 2 addresses the specific aim 1. It deals with the development of highly sensitive
LSPR sensor and its application on detection of small heavy metal molecule binding. A
self-assembled 3D hydrogel–nanoparticle composite integrated LSPR sensor is reported.
The novel assembled substrate was developed by means of a surface mediated radical copolymerization process to obtain a highly sensitive hydrogel-based thin film that
possesses specific binding sites for target analytes.

Initially, amino group modified

AuNPs were covalently linked to acrylic acid monomer. NIPAAm and AuNPs linked
AAc monomers were randomly co-polymerized by the “grafting from” method in the
presence of initiator and crosslinker onto the sensing surface. Surface charecterization
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techniques were utilized to evaluate the thickness and composition of the hydrogelnanoparticle film. The sensing platform was employed to study the binding kinetics and
conformational changes of the ArsA ATPase as a consequence of binding trivalent
arsenicals under a variety of conditions. ArsA, the catalytic subunit of the ArsAB As(III)
translocating ATPase, is one of the five proteins encoded by the ars operon of plasmid
R773 in cells of E. coli, that confers resistance to trivalent and pentavalent salts of the
metalloid arsenic.

LSPR measurements indicate that the 3D hydrogel-nanoparticle

coated sensors exhibited a higher sensitivity than that of the 2D AuNPs decorated
sensors. Binding of As(III) to ArsA is greatly facilitated by the presence of magnesium
ion and ATP.

Chapter 3 addresses the specific aim 2. It describes the sensing platform upgrade for
biomarker study from living cell model.

A SPR biosensor which is capable of

monitoring proteomic biomarker secretion from living cells is reported here. The sensing
strategy is based on the integration of a mini cell culture system within the traditional
SPR sensing platform. SKOV-3 cells were incubated in the gelatin coated SPR flow
chamber during the experiment. VEGF secretion from living SKOV-3 ovarian cancer
cells was measured for concept demonstration. Fluorescent imaging was utilized to
demonstrate cell viability in the SPR flow chamber. Rapid VEGF secretion from SKOV3 cells induced by Ca2+ ionophore was successfully monitored. The amount of VEGF
released from SKOV-3 cells was determined by VEGF calibration curve. Cell number
study reveals the relationship between SKOV-3 cell number and VEGF secretion amount,
which helps to provide a strategy for accurate prediction of carcinoma cell number. By
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modifying the surface functionalization of the SPR assay, this biosensor might open up
new horizons for detection and analysis of biomarker from living cells and tissue for
different diseases.

Chapter 4 addresses the specific aim 3. It involves the evaluation of drug regulation on
VEGF binding with living cell model. VEGF is one of the most important and best
documented angiogenic factors, which is involved in the instigation of various types of
tumor. VEGF-VEGFR binding process is the key point of angiogenesis, which is also the
target of many angiogenesis inhibition therapy strategies. The purpose of this study was
to construct a biomimic system of VEGF-VEGFR signaling pathway based on the
platform described in chapter 3 for drug regulation study. Bevacizumab is a humanized
anti-VEGF monoclonal antibody which is a FDA approved medicine for cancer therapy
by regulating VEGF-VEGFR binding interaction. It has been proven to be clinically
effect on angiogenesis inhibition. In this study, we employed bevacizumab as a model to
demonstrate and evaluate our biomimic system for drug regulation study.

Binding

affinity and kinetics were studied for VEGF-VEGFR and VEGR-bevacizumab
interactions.

Results indicate that bevacizumab has higher binding affinity and

association rate constant towards VEGF comparing with VEGFR. Biomimic study of
bevacizumab regulation to the VEGF-VEGFR signaling pathway of living SKOV-3 cells
shows successful blockage of the VEGF-VEGFR binding and activation process. A
similar protocol can be used to evaluate drug regulation mechanisms in other disease
models.
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5.2. Future Work
The LSPR biosensors developed for the arsenic detoxification pathway study will be
further employed for the study of other proteins encoded by the ars operon. Binding
kinetics of ArsA-As(III) interaction under the combined effect of ArsD and MgATP can
be further investigated. Based on previous publication, the ars operon is also able to
detoxify organic arsenic components. The LSPR biosensors could be useful for the study
of interactions between ars proteins and organic arsenic components.

The signaling pathway biomimic system is capable of living cell studies, but it is lack of
long term study capability. A temperature and CO2 controled mini cell culture system
will be intergrated to the SPR biomimic systems to achieve long term real-time
measurement. Regulations by other medicine on the VEGF-VEGFR signaling pathway
can also be investigated in the future. The SPR biosensors will also be tested for their
sensitivity, specificity, reproducibility, etc. on the detection of biomarkers in body fluid
from real patients. We have demonstrated the detection and kinetics studies on proteins
using SPR. It will be very interesting to test the ability of detecting other types of cellular
secretion (DNA, RNA, exosomes, etc.) on this sensing platform. The most promising
potential of SPR in medical applications is early diagnosis. However, as we mentioned in
chapter 1, SPR instruments are expensive and lack of portability. Research efforts should
be put onto the development of cheaper, smaller and lighter SPR sensing platforms to
make this technology more accessable for early diagnosis.
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